- Home
- PMVP vs IMUX Comparison
PMVP vs IMUX Comparison
Compare PMVP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | IMUX |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 75.2M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PMVP | IMUX |
|---|---|---|
| Price | $1.50 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $5.00 | $4.25 |
| AVG Volume (30 Days) | 824.8K | ★ 3.0M |
| Earning Date | 03-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.51 |
| 52 Week High | $1.88 | $1.51 |
Technical Indicators
Market Signals| Indicator | PMVP | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 55.82 |
| Support Level | $1.32 | $0.64 |
| Resistance Level | $1.64 | $1.17 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 8.54 | 33.55 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.